The $140,672,343 man: Why does Brent Saunders have the richest golden parachute in biopharma?
Live by the deal, profit by the deal.
If any company can succeed where Pfizer failed and take over Allergan, CEO Brent Saunders may be perfectly content to step aside. In a new listing of the top golden parachutes on record, Bloomberg put the wheeler-dealer in the number 5 position overall, with $140,672,343 waiting by the exit. And that’s the biggest, brightest golden parachute in biopharma’s corporate closet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.